share_log

EFFECT: Others

SEC ·  Jul 17 18:08

Summary by Futu AI

The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.
The United States Securities and Exchange Commission (SEC) has declared ZyVersa Therapeutics, Inc.'s submission effective as of July 16, 2024. The company, known for its focus on developing advanced therapies, had its filing accession number 0001493152-24-027033 and submission type POS AM acknowledged by the SEC. This notice of effectiveness is a significant step for ZyVersa Therapeutics, indicating that the regulatory body has reviewed and accepted the company's submission.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated